Difluoro Ketone Peptidomimetics Suggest a Large S1 Pocket for Alzheimer's γ-Secretase: Implications for Inhibitor Design
- 22 August 2000
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (18) , 3434-3442
- https://doi.org/10.1021/jm000100f
Abstract
The final step in the generation of the amyloid-beta protein (Abeta), implicated in the etiology of Alzheimer's disease, is proteolysis within the transmembrane region of the amyloid precursor protein (APP) by gamma-secretase. Although considered an important target for therapeutic design, gamma-secretase has been neither well-characterized nor definitively identified. Previous studies in our laboratory using substrate-based difluoro ketone and difluoro alcohol transition-state analogue inhibitors suggest that gamma-secretase is an aspartyl protease with loose sequence specificity. To further characterize the active site of gamma-secretase, we prepared a series of difluoro ketone peptide analogues with varying steric bulkiness in the P1 position and tested the ability of these compounds to inhibit Abeta production in APP-transfected cells. Incorporation of bulky, aliphatic P1 side chains, such as sec-butyl or cyclohexylmethyl, led to increased gamma-secretase inhibitory potency, suggesting a large S1 pocket to accommodate these substituents and providing further evidence for loose sequence specificity. The cyclohexylmethyl P1 substituent allowed N-terminal truncation to a low-molecular-weight compound (<600 Da) that effectively blocked Abeta production (IC(50) approximately 5 microM). This finding suggests that optimal S1 binding may allow the development of potent inhibitors with ideal pharmaceutical properties. Moreover, a difluoro alcohol analogue with a cyclohexylmethyl P1 substituent was equipotent with its difluoro ketone counterpart, providing strong evidence that gamma-secretase is an aspartyl protease. All new analogues inhibited total Abeta and Abeta(42) production with the same rank order of potency and increased Abeta(42) production at low concentrations, providing further evidence for distinct gamma-secretases that are nevertheless closely similar with respect to active site topology and mechanism.Keywords
This publication has 27 references indexed in Scilit:
- Translating cell biology into therapeutic advances in Alzheimer's diseaseNature, 1999
- Inhibition of β-amyloid formation as a therapeutic strategyExpert Opinion on Therapeutic Patents, 1999
- Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic miceProceedings of the National Academy of Sciences, 1998
- Alzheimer's Disease--Genotypes, Phenotype, and TreatmentsScience, 1997
- Dissecting intrinsic chaperonin activityProceedings of the National Academy of Sciences, 1997
- Activation of microglial cells by β-amyloid protein and interferon-γNature, 1995
- Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.Proceedings of the National Academy of Sciences, 1994
- Cell Biology of the Amyloid beta-Protein Precursor and the Mechanism of Alzheimer's DiseaseAnnual Review of Cell Biology, 1994
- The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's diseaseBiochemistry, 1993
- Plasticity in the frequency representation of primary auditory cortex following discrimination training in adult owl monkeysJournal of Neuroscience, 1993